You can buy or sell Epizyme and other stocks, options, ETFs, and crypto commission-free!
Epizyme, Inc. Common Stock, also called Epizyme, is a clinical-stage biopharmaceutical company. Read More The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
— per share
Expected Aug 6, Pre-Market